Disease name and definition
===========================

Malignant mesothelioma is a cancer originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis \[[@B1]\]. Its distribution may be uni- or multifocal or may involve the lining cells in a continuous manner.

Epidemiology and aetiology
==========================

Before 1950, malignant mesothelioma was so rare that some pathologists even questioned its existence \[[@B2]\]. However, the increasing use of asbestos after the second world war led to the description of a causal relationship between asbestos exposure and the development of mesothelioma in 1960 \[[@B3]\]. Although its use was widely abandoned in the western world in the 1980s, the long latency period between exposure to asbestos and onset of mesothelioma, which can range from 15 to 60 years \[[@B4],[@B5]\], meant that the mortality rates from mesothelioma have continued to rise. In the USA the annual deaths from mesothelioma peaked at 3060 in 2002 and have subsequently declined, however the incidence of mesothelioma will continue to rise in the UK until it reaches a peak in about the year 2020 \[[@B6]\]. According to data gathered in the US Surveillance Epidemiology and End Results programme for 1973--1992, there has been virtually a constant rate of mesothelioma in females but a consistently higher rate for males. In the 1960s a mesothelioma register was set up in the UK to systematically record the mortality rates from mesothelioma and to try to identify the incidence of tumour development without known occupational exposure. It is predicted that around 90,000 deaths will occur from mesothelioma by 2050, with 65,000 of these occurring from 2002 onwards \[[@B7]\].

Asbestos is a naturally occurring fibrous silicate, and the risk of developing mesothelioma depends on the exposure to different types of the asbestos mineral fibre. The main asbestos mineral groups are serpentine fibres, which are long and curly, or amphibole fibres which are straight and rod-like. This distinction is important as the serpentine fibre shape is more easily cleared from the respiratory tract. Epidemiologic data suggests that the amphibole, crocidolite, is associated with the highest risk of mesothelioma \[[@B8]\] and that the serpentine fibre, chrysotile has the lowest. The diagnosis of mesothelioma is directly attributable to occupational asbestos exposure; however there is evidence that mesothelioma may result from both para-occupational exposure (*e.g*.: women having laundered their husband\'s overalls) and non-occupational \"environmental\" exposure \[[@B9]\]. Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos in both animals \[[@B10]\] and humans \[[@B8]\], and a recent review suggests a spontaneous mesothelioma rate in humans of around one per million \[[@B11]\].

Non-asbestos mineral fibres have also been shown to induce mesothelioma, such as erionite found in certain areas of Turkey \[[@B12]\] or tremolite in north-western Greece \[[@B13]\], and whilst not specifically mined for commercial purposes, tremolite is often found as a contaminant of chrysotile asbestos and has been causally linked with an increased risk of mesothelioma \[[@B14]\]. The role of Simian virus (SV-40) in the pathogenesis of mesothelioma is more controversial; SV-40 was found to contaminate polio vaccines in the 1950s and 60s in the UK, and although it has been suggested that it is a causative factor in the development of mesothelioma \[[@B15]-[@B17]\], recent studies have found no link \[[@B18]-[@B20]\].

Clinical description
====================

Mesothelioma is primarily a disease of adults and usually presents in the fifth to seventh decades, and 70--80% of cases occur in men. Those diagnosed between the ages of 20 to 40 years usually have a history of childhood exposure \[[@B1]\]. Typical presenting features are those of chest pain, dyspnoea or both \[[@B11],[@B21]\], and in one series up to a third of patients presented with breathlessness due to a pleural effusion without chest pain \[[@B22]\]. When it occurs, the chest pain tends to be dull or boring in nature, but a pleuritic-type pain can occur in the presence of pleural effusions. Involvement of the mediastinal structures is well recognized but hoarseness of the voice and superior vena caval obstruction only rarely causes major symptoms. Dysphagia can also occur but this is a late finding. Unlike bronchogenic carcinomas, presentation with haemoptysis, lymphadenopathy and metastatic symptoms are unusual. A chest wall mass, weight loss and sweating are less common presentations, as is peritoneal mesothelioma although involvement may be found in up to one third of cases at autopsy. Presentation of peritoneal mesothelioma is with non-specific symptoms including loss of appetite, nausea and vomiting, diarrhoea or constipation and occasionally ascites. Small bowel obstruction is usually a late feature, and overall the prognosis of peritoneal mesothelioma is worse than pleural mesothelioma with a mean survival time of about 7 months \[[@B11]\].

Physical examination is usually unremarkable except for signs of pleural effusion and pleural thickening due to tumour infiltration. Finger clubbing is more common than in benign asbestos related pleural disease, and can occur in up to 30% of cases \[[@B23]\]. The tumour originates mainly on the parietal pleura and spreads via the fissures, to encase the lung surfaces. Infiltration of the pericardium can result in signs of cardiac tamponade, and mesothelioma can grow along needle tracks and incisions. Blood tests can reveal an elevated erythrocyte sedimentation rate (ESR) \[[@B24]\], and there have been isolated case reports of mesothelioma associated with autoimmune haemolytic anaemia \[[@B25]\].

Diagnosis and differential diagnosis
====================================

The combination of accurate history, examination, radiology and the acquisition of pathology is essential in the diagnosis of mesothelioma. A careful history of asbestos exposure is essential, and the identification of at-risk occupations are strong markers of exposure. However, the delay between exposure and presentation may naturally preclude accurate recall of occupational exposure and working conditions which may have occurred up to 60 years previously.

In those patients with a pleural effusion, sampling of the fluid for cytological examination is the first step in confirming the diagnosis. Pleural fluid cytology is positive for malignant cells in about a third of cases \[[@B1]\] and if the clinical, radiological and cytological results support a diagnosis of mesothelioma then this can be accepted. However, it is uncommon for the definitive diagnosis to be made on pleural fluid cytology alone and pleural biopsy for tissue diagnosis is therefore recommended. A contrast enhanced computed tomogram (CT) scan is essential to both identify the extent of the disease, and help guide a percutaneous biopsy if the pleural fluid cytological analysis is not sufficient.

Radiological findings
---------------------

Radiological imaging is essential for the diagnosis, staging and management of mesothelioma. X-ray, CT, magnetic resonance imaging (MRI) and positron emission tomography (PET) have all been used to evaluate the disease.

### CT

Intravenous contrast-enhanced CT is the primary imaging modality for suspected pleural malignant disease. CT allows visualisation of the whole pleural surface and diaphragm and use of a 45--60 second scan delay enables the pleural surfaces to be studied whilst still allowing assessment of the mediastinal nodes \[[@B26]\]. A standard protocol should include the liver and adrenal glands, but in cases where there is a past history of abdominal or pelvic malignancy, the scan should also include the lower abdomen and pelvis \[[@B11]\].

Distinguishing malignant from benign pleural disease can be challenging. The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of \> 1 cm and 4) mediastinal pleural involvement \[[@B27]\]. The specificities of these findings were 100%, 94%, 94% and 88% respectively. The sensitivities were 41%, 51%, 36% and 56% respectively. The presence of bilateral pleural calcification on CT is uncommon in malignant mesothelioma \[[@B27]\]. A significant reduction in thoracic volume seen on CT is more common, however, occurring in up to 73% of cases according to some series \[[@B28]\]. Whilst these features have a high positive predictive value, absence of these signs does not reliably exclude the diagnosis of pleural malignancy.

### MRI

MRI screening is not used routinely in the assessment of malignant mesothelioma, however in patients with potentially resectable disease, MRI can help to provide additional staging information over and above CT. Using gadolinium enhancement, MRI can improve the identification of tumour extension into the diaphragm or chest wall, allowing better assessment of the individual for surgical treatment. MRI also is the imaging modality of choice in those in whom intravenous iodinated contrast is contraindicated \[[@B29]\].

### PET

The standardized uptake value (SUV) in PET is a semi-quantitative measure of the metabolic activity of a lesion and the SUV is significantly higher in mesothelioma than in other benign pleural diseases such as pleural plaques or inflammatory pleuritis \[[@B29],[@B30]\], and one study found PET scanning to have a 96.8% sensitivity and an 88.5% specificity at distinguishing benign from malignant pleural disease \[[@B31]\]. PET scanning has also increased the accuracy in diagnosing mediastinal nodal metastases \[[@B30]\] and therefore the combination of metabolic and anatomical information provided by PET makes it useful in the staging and preoperative evaluation of mesothelioma. PET may also help as a guide to the optimal site for CT guided pleural biopsy, and there is evidence that changes in the fluorodeoxyglucose (FDG) uptake within the tumour might indicate response to treatment suggesting its role in the assessment of response to both chemotherapy and chemo-radiotherapy \[[@B32]\].

### Staging and assessment of disease response

At least six different staging systems have been suggested for malignant mesothelioma, but none have been accurately shown to predict survival. Currently, a TNM staging system (Table [1](#T1){ref-type="table"}) similar to that used in non-small cell lung carcinoma has been proposed by the International Mesothelioma Interest Group (IMIG) \[[@B33]\].

###### 

IMIG TNM staging system

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Primary tumour (T)**   
  ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  T1a                      Tumour limited to the ipsilateral parietal including mediastinal and diaphragmatic pleura, no involvement of the visceral pleura

                           

  T1b                      Tumour involving the ipsilateral parietal including mediastinal and diaphragmatic pleura, scattered foci of tumour also involving the visceral pleura

                           

  T2                       Tumour involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral pleura) with at least one of the following features:\
                           • involvement of diaphragmatic muscle\
                           • confluent visceral pleural tumour (including the fissures)\
                           • extension of tumour from visceral pleura into the underlying pulmonary parenchyma

                           

  T3                       Locally advanced but potentially resectable tumour; tumour involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral pleura) with at least one of the following features:\
                           • involvement of the endothoracic fascia\
                           • extension into the mediastinal fat\
                           • solitary, completely resectable focus of tumour extending into the soft tissues of the chest wall\
                           • non transmural involvement of the pericardium

                           

  T4                       Locally advanced technically unresectable tumour; tumour involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral) with at least one of the following features:\
                           • diffuse extension or multifocal masses of tumour in the chest wall with or without associated rib destruction\
                           • direct transdiaphragmatic extension of tumour to the peritoneum\
                           • direct extension of tumour to the contralateral pleura\
                           • direct extension of tumour to one or more mediastinal organs\
                           • direct extension of tumour into the spine: tumour extending through to the internal surface of the pericardium with or without a pericardial effusion\
                           • tumour involving the myocardium

                           

  **Lymph nodes (N)**      

                           

  Nx                       Regional lymph nodes cannot be assessed

                           

  N0                       No regional lymph node metastases

                           

  N1                       Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes

                           

  N2                       Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary nodes

                           

  N3                       Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes

                           

  **Metastases (M)**       

                           

  Mx                       Presence of distant metastases cannot be assessed

                           

  M0                       No distant metastasis

                           

  M1                       Distant metastasis present
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tumour response to treatment is an important surrogate for patient benefit. The World Health Organization (WHO) criteria for tumour response were most useful for measuring bi-dimensional lesions, whereas the irregular growth pattern of mesothelioma as a rind around the chest wall makes these criteria poorly applicable \[[@B34]\]. More recently, the Response Evaluation Criteria in Solid Tumours (RECIST) \[[@B35]\] uses a uni-dimensional measurement of tumour size to assess response, but this is based on the assumption that tumours are largely spherical, so again there are limitations to the applicability of this technique in the assessment of malignant mesothelioma.

A modified RECIST criteria has now been published, however, with particular reference to malignant mesothelioma \[[@B36]\]. Assessment of response to treatment is now made by measuring uni-dimensional tumour thickness perpendicular to the chest wall in 2 sites at three different levels on CT.

Pathological findings
---------------------

According to the WHO classification, malignant mesothelioma can be classified as epithelioid, sarcomatoid, or biphasic based on tissue obtained by biopsy. The pathological diagnosis is reached with the aid of immunohistochemistry to demonstrate the presence of mesothelial, epithelial, or true sarcomatous differentiation in the malignant cells \[[@B37]\]. The reported diagnostic yield from CT guided biopsy varies from 60% with a single attempt up to 85% with multiple attempts \[[@B38]\]. Ultimately, however, the highest yields are obtained with open or thoracoscopic pleural biopsy.

There is currently no individual immunohistochemical mesothelial marker that provides 100% specificity and high sensitivity for the diagnosis of malignant mesothelioma \[[@B37]\] and so a number of mesothelial and epithelial markers have been developed. Clearly, distinguishing a malignant pleural process from an inflammatory process is a priority and immunohistochemistry has demonstrated that mesothelioma frequently shows immunoreactivity for keratin, p53 and epithelial membrane antigen (EMA) which is unusual for benign pleural disease.

Differentiating malignant mesothelioma from other malignancies, however, can be more difficult as mesotheliomas, especially those of the epithelioid type, can mimic several other tumours. Again, immunohistochemistry can help in the differentiation of mesothelioma and markers such as mesothelin, cytokeratin 5/6, calretinin, thrombomodulin and WT-1 have been used. The most specific and sensitive markers for mesothelioma are mesothelin (in epithelioid mesothelioma), calretinin and cytokeratin 5/6. However, according to a recent review article, mesothelin is positive in 27% of squamous cell carcinomas, and calretinin and cytokeratin 5/6 can be raised in both squamous cell carcinoma of the lung and adenocarcinoma of both the lung and other sites \[[@B37]\]. Clearly there can be difficulty in making the diagnosis, and so usually a panel of two positive and two negative markers will be sufficient to confirm the presence of malignant mesothelioma.

### Serum markers in the diagnosis of mesothelioma

Reliably diagnosing malignant mesothelioma early in the disease is notoriously difficult due to the variability in time to presentation from exposure in the disease. Recently there has been much interest in the use of serum markers for the diagnosis of the disease. The ideal serum marker would be one that is able to offer: 1) early diagnosis, 2) identification of all the subtypes, 3) differentiation of malignant mesothelioma from benign pleural disease and other metastatic pleural malignancies, and 4) be able to track response to therapy and predict survival. As yet no such ideal marker exists, but studies have suggested the use of osteopontin, mesothelin or megakaryocyte potentiating factor in this role.

Osteopontin is a glycoprotein that is over-expressed in lung, breast, colorectal, gastric and ovarian carcinomas and in melanoma. Increased levels correlate with tumour progression, invasion and metastases. Although increased levels do not exclude other malignancies, recent data suggest that osteopontin has great potential use as a marker for mesothelioma \[[@B39]\] and has a positive predictive power for mesothelioma equivalent to Ca-125 for ovarian cancer. Studies have suggested a sensitivity and specificity for mesothelioma of 77% and 85% respectively \[[@B40]\].

Mesothelin is a membrane bound glycoprotein expressed by mesothelial cells and over expressed in malignancy, especially mesothelioma \[[@B41]\]. Soluble mesothelin related proteins (SMRP) are serum proteins thought to be released by alternative splicing of the mesothelin protein and thereby preventing adherence to cell membranes. Serum concentrations are increased in malignant mesothelioma, and therefore this protein is a potential serum marker for the disease \[[@B42]\]. However, although most patients with mesothelioma have raised serum levels of SMRP, giving a sensitivity of between 80--83% and specificity between 80--100% \[[@B43]-[@B45]\], it is mostly associated with the epithelioid sub-type, leading to difficulties in identifying the other sub-types of mesothelioma, especially sarcomatoid, using this marker alone \[[@B46]\]. Nevertheless a commercially available FDA-approved assay, MESOMARK (Fujirebio Diagnostics Inc, Malvern, PA, USA), has been recently approved for use in the monitoring of disease in epithelioid and biphasic mesothelioma, and data seems to support its usefulness \[[@B47]\].

Megakaryocyte Potentiating Factor (MPF) is secreted by cells of several mesothelioma cell lines. In recent studies, MPF was elevated in 91% of 56 malignant mesothelioma patients compared with controls, and levels returned to normal after surgery in patients with peritoneal mesothelioma \[[@B46],[@B48]\]. This might make MPF useful in the monitoring of treatment response in mesothelioma.

Management
==========

Because there can be difficulty reaching a diagnosis of mesothelioma despite radiology, cytology and biopsy, the general management of patients with mesothelioma should be under a multidisciplinary team including respiratory physicians, oncologists, radiologists, palliative care physicians and lung cancer specialist nurses. In addition, once the diagnosis has been reached, there should be close liaison with the patient\'s primary care physician, and both the primary care physician and family should be warned that, at least in the UK, a post mortem examination will usually be required after the death of a patient with mesothelioma.

The general treatment strategy of mesothelioma should cover the following areas:

• Management of pleural effusions

• Radiotherapy to intervention sites

• Suitability for radical surgery

• Suitability for clinical trial entry and chemotherapy

• Compensation issues

• Palliation of symptoms and end-of-life care

Management of pleural effusions
-------------------------------

Management of malignant pleural effusions begins with therapeutic thoracocentesis, which assesses the response of dyspnoea to fluid removal. If symptoms do not respond to thoracocentesis, alternative causes of dyspnoea should be sought such as pulmonary thromboembolic disease, or lymphangitis carcinomatosis. Early, successful management on pleural effusions with pleurodesis is essential for the palliation of symptoms and the prevention of a trapped lung. However with repeated thoracocentesis, the pleural fluid may undergo loculation making it difficult to drain subsequently and also the risk of pleural infection increases. If a conclusive diagnosis has been made, chemical pleurodesis can be performed via a small bore intercostal chest drain (9--14F), which has equivalent success rates to larger bore chest drains with the added benefit of patient comfort \[[@B49],[@B50]\]. The ideal sclerosing agent is sterile talc, with success rates between 70 and 96% \[[@B50]-[@B52]\], although care must be taken to ensure the talc particles are of the optimal calibration to prevent the rare risk of adult respiratory distress syndrome (ARDS) \[[@B53]\].

If a firm diagnosis is yet to be made, and the patient is fit enough for surgery, then thoracoscopy is an extremely useful technique in the management of suspected malignant pleural effusions. This procedure allows visualisation of the pleural surface, enables histological sampling for diagnosis and allows complete drainage of the effusion followed by pleurodesis via talc poudrage.

In patients with a trapped lung, or in whom pleurodesis has failed, a pleuro-peritoneal shunt can be considered. Whilst symptoms can improve in over 90% of patients, complications (including shunt occlusion and infection) occur in 15% and therefore their use is diminishing \[[@B54]\]. More recently, an ambulatory pleural drainage system (Pleur~x~Pleural Catheter, Denver Biomedical Inc, USA) has been developed. This system enables the patient to control the pleural effusion at home by means of a long-term drainage catheter and vacuum bottles. This might help patients with trapped lungs as it both avoids the need for surgical intervention, and palliates dyspnoea \[[@B55]\].

Radiotherapy
------------

### Palliative radiotherapy

Radiotherapy can be used to control local tumour growth and occasionally causes regression of disease, but there is no evidence that radiotherapy alone affects survival \[[@B56]\]. It has, however, been shown to be helpful in the palliation of pain \[[@B57]\], and approximately half the patients treated with palliative radiotherapy derive some benefit \[[@B58]\]. It also appears that short courses of radiotherapy (for example 20 Gy in 5 fractions) are as effective as longer courses such as 30 Gy in 10+ fractions \[[@B59]\], although there is a total dose response effect \[[@B60]\]. Unfortunately, radiotherapy is rarely helpful in either the palliation of dyspnoea or the management of symptoms of mediastinal infiltration such as superior vena caval obstruction (SVCO), and alternative methods of treatment such as SVC stenting should be sought \[[@B11],[@B61]\].

### Radical radiotherapy as a single modality

Whilst hemithorax irradiation may provide symptomatic benefit, no studies have shown that it prolongs survival \[[@B61]\]. Mesothelioma can involve large areas of the pleural cavity and use of radical radiotherapy over large fields places a range of organs such as lungs, liver, spinal cord or heart at a significant risk of dose related damage. As a result, a recent Cochrane review found no randomised clinical trial evidence to support the use of radical radiotherapy alone (or in combination with other treatment modalities) in mesothelioma \[[@B62]\], and this treatment option has been shown to confer a significant mortality, with rates as high as 17% in one series \[[@B59]\].

### Radiotherapy as part of multimodality treatment

Failure to increase survival using single treatment modalities has led to a multimodality approach to treatment in mesothelioma. Combining debulking surgery with radiotherapy is the cornerstone of this approach and can both reduce systemic recurrence and influence the natural history of the disease \[[@B63],[@B64]\]. Typically, hemithorax radiotherapy is combined with extra pleural pneumonectomy (EPP -- see later) and correctly staged patients with epithelioid mesothelioma can have median survival rates of 33 months \[[@B65]\]. Due to the large, irregular nature of malignant mesothelioma along with the close proximity of other organs, a more directed modality of irradiation which could help improve local tumour control whilst limiting exposure to surrounding organs has been developed, known as intensity modulated radiotherapy (IMRT) \[[@B66]\]. Despite the possibilities for improved tumour control, however, IMRT still carries a potential risk of fatal pulmonary toxicity in mesothelioma \[[@B67],[@B68]\].

### Prophylactic radiotherapy

Mesothelioma may seed malignant cells in procedure scars. Whilst pain from these metastases is rare, they can become uncomfortable, and evidence has suggested that radiotherapy to intervention sites can prevent this complication \[[@B69],[@B70]\]. Whilst this practice is recommended in current guidelines \[[@B11]\], evidence is emerging that it should only be offered to those patients who are symptomatic from these subcutaneous tumours as the radiotherapy itself may have side effects \[[@B71],[@B72]\].

Surgery
-------

The role of surgery in the treatment of malignant mesothelioma is still uncertain. The three most common surgical procedures are surgical pleurodesis via video assisted thoracoscopic surgery (VATS), debulking surgery (also known as cytoreductive surgery or pleurectomy/decortication (P/D)) and extra pleural pneumonectomy (EPP). This comprises en-bloc resection of the parietal pleura, lung, pericardium and diaphragm and mediastinal nodes \[[@B56]\]. P/D allows the removal of the visceral, parietal and pericardial pleura as well as debulking the tumour and is therefore less demanding, with mortality rates \< 5% \[[@B73]\]. P/D has limitations, however, as it does not remove the tumour completely, and the preservation of the ipsilateral lung makes postoperative radiotherapy difficult due to the risk of pulmonary side effects \[[@B74]\]. The impact of P/D on overall survival is contentious, with some evidence suggesting that P/D surgery via a VATS approach may provide a survival benefit in patients with advanced disease not suitable for EPP \[[@B75]\], whilst other studies do not clearly distinguish the benefit of P/D over EPP \[[@B76]\].

EPP is a much more demanding procedure with morbidity rates as high as 60% \[[@B77]\] and mortality rates of 4--9% \[[@B11],[@B78],[@B79]\]. However, the pneumonectomy in EPP allows the use of high dose hemithoracic radiotherapy, and this combined treatment has been shown to reduce local recurrence and prolong survival in early disease \[[@B65]\]. As a result, as part of the trimodality approach to treatment with surgery chemotherapy and radiotherapy, EPP has arisen as the surgical treatment of choice, albeit without clear randomised controlled trial evidence \[[@B78]\]. In order to clarify this issue, a large randomized trial (Mesothelioma And Radical Surgery (MARS)) is underway \[[@B80]\]. In this trial, EPP is sandwiched between induction chemotherapy and radical radiotherapy. The control arm offers full active tri-modality therapy, although the surgery is limited to debulking surgery. In addition patients receive the same induction chemotherapy and are given radiotherapy to any drain or port sites.

Chemotherapy
------------

The use of chemotherapy in malignant mesothelioma aims to lengthen survival, improve quality of life and provide symptomatic relief. Currently, there is no single drug or combination therapy that could be considered as standard treatment for mesothelioma. A variety of single agent and combination regimens have been tried in clinical trials with response rates of between 0% and 45% \[[@B81]\].

A review of studies by Berghmans *et al*\[[@B82]\] revealed that cisplatin was the most effective single agent for mesothelioma, with carboplatin having similar activity, and in combination with doxorubicin provided a response rate superior to other regimens studied, although there was no clear benefit in terms of survival. Single agent vinorelbine and combination treatment MVP (mitomycin C, vinblastine and cisplatin) have also been shown to provide good symptom relief with acceptable toxicity \[[@B83]-[@B85]\].

Recently, there has been much interest in the use of the antifolate pemetrexed (Alimta; Eli Lilly). Pemetrexed exerts its effect by interrupting folate dependent metabolic synthesis of purines and pyrimidines (the building blocks of DNA and RNA), and a Cochrane review of the effectiveness of combination treatment with cisplatin/pemetrexed \[[@B81]\] suggests a survival benefit, albeit with increased toxicity which is reduced by the co-administration of vitamin B12 and folate supplements. Much of the evidence supporting the use of pemetrexed comes from a single study \[[@B86]\] in which 331 patients, fully supplemented with vitamin B12, demonstrated a median survival of 13.3 months with combination pemetrexed/cisplatin compared to 10.0 months with cisplatin alone (*p*= 0.05). This was associated with a significant improvement in quality of life and symptom relief compared to cisplatin alone \[[@B87]\]. Combination with carboplatin instead of cisplatin, however, may be an alternative regimen which provides similar efficacies and reduced side effects \[[@B88]\]. An alternative antifolate agent, raltitrexed, has also been shown to confer a survival benefit in combination with cisplatin, with median overall survival increasing from 8.8 months (CI 7.8--10.8) with cisplatin alone to 11.4 months (CI 10.1 to 15) with combination cisplatin-raltitrexed (*p*= 0.05) \[[@B89]\]. Although this study only demonstrated borderline significance, likely as a result of sample size, the results of these trials mean that combination cisplatin and an antifolate should be the reference regimen in mesothelioma. Recent advances now favour the use of neoadjuvant chemotherapy followed by EPP and radiation for malignant mesothelioma; Weder *et al*recently published their experience of a prospective trial of neoadjuvant chemotherapy consisting of cisplatin and gemcitabine followed by EPP, demonstrating a median survival of 23 months \[[@B90]\]. Similarly, Flores *et al*prospectively studied patients given induction gemcitabine and cisplatin followed by EPP. Median survival of all patients in the study was 19 months, but those patients who completed induction chemotherapy and subsequently underwent EPP had a median survival of 33.5 months \[[@B91]\].

As a result, all patients who are fit enough (ECOG performance status 0--2) should have the opportunity to discuss the merits of chemotherapy in mesothelioma with an oncologist \[[@B11]\], in the knowledge that there are no published data which compares survival or symptom control in patients treated with chemotherapy or best supportive care only. The first such trial (MSO-1) \[[@B92]\] is complete, and the preliminary results were published in abstract form in 2007 \[[@B93]\]. These results suggest that the addition of chemotherapy to active symptom control with best supportive care did not infer a significant survival benefit in mesothelioma, however this trial was started before the emergence of pemetrexed.

Supportive and palliative care
------------------------------

Given that malignant mesothelioma has a poor overall prognosis, referral of patients to specialist palliative care services will be appropriate at some time in the disease course. Most patients need palliation of symptoms early on in the course of the disease and recognition of this by the patient, family and primary care physician is essential in the management of the patient with mesothelioma. The use of a central lung cancer nurse specialist provides a means by which the patient can gain access to the delivery of care needed for this disease, through the following core elements \[[@B11]\]:

• Communication

• Information

• Coordinated care between respiratory physicians, oncologists, radiologist and palliative care specialists

• Nursing care

• Accessibility

• Support

Prognosis and survival
======================

Life expectancy in malignant mesothelioma is poor, with median survival varying between 8 and 14 months \[[@B11]\]. The Cancer and Leukaemia Group B, and the European Organization for Research and Treatment of Cancer have analysed large numbers of patients enrolled in treatment trials for mesothelioma and have identified the following poor prognostic factors:

• Non-epithelioid histology

• Poor performance status

• Chest pain

• Age older than 75

• Male gender

• White blood cell count 8.3 × 10^9^/L or greater

• Platelets greater than 400,000 **μ**L

• LDH greater than 500 IU/L

The majority of patients who survive for more than 2 years have epithelioid histology and death from mesothelioma tends to be due to respiratory failure.

Compensation issues
===================

Eligibility for compensation for mesothelioma may vary from country to country. In the UK for example, a diagnosis of mesothelioma allows compensation via the Industrial Injuries Disablement Benefit, War Pensions Scheme or through a Common Law claim from the firm/firms where the asbestos exposure occurred. Patients who cannot identify occupational exposure to asbestos are not entitled for compensation, however pathological confirmation of the diagnosis is not mandatory; establishing the diagnosis and causation on the balance of probability is sufficient, although an unequivocal diagnosis obviously removes any cause for debate. Earlier this year, a new legislation was made in the UK Child Maintenance and Other Payments Act whereby dependants of persons with mesothelioma became eligible to claim for lump-sum compensation after death <http://www.opsi.gov.uk/acts/acts2008a>.
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